The DNA repair drugs market is expected to register a CAGR of nearly 13% over the forecast period, 2022-2027.
The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the DNA repair drugs market. DNA repair drugs are majorly used for cancer. Thus, the delay in cancer treatment worldwide significantly impacted the demand for these drugs after the onset of the pandemic. For instance, as per the study published in December 2021 on "Impact of the COVID-19 pandemic on the diagnosis of new cancers: A national multicentre study of the Veterans Affairs Healthcare System, from 2018 through 2020, there were 4.1 million cancer-related encounters, 3.9 million relevant procedure, and 251,647 new cancer cases diagnosed. As per the study, as compared to the annual averages in 2018 through 2019, colonoscopies in 2020 decreased by 45%, whereas prostate biopsies, chest computed tomography scans, and cystoscopies decreased by 29%, 10%, and 21%, respectively, and new cancer diagnoses decreased by 13% to 23%. Thus, as there was a delay in diagnostic procedures, the demand for oncology drugs was also negatively impacted.
Also, as per a February 2021 published article titled, "Dramatic drop in new cancer drug trials during the COVID-19 pandemic", the data revealed a 60% decrease in new clinical trials for cancer drugs and biological therapies during the pandemic, further highlighting the Impact that COVID-19 is having on oncology research. This further indicates the slow growth of the market amid the pandemic. Moreover, COVID-19 also led to supply chain disruptions of pharmaceutical and biotechnology products. However, the scope of market growth is expected to expand amid the pandemic with the introduction of vaccines, upliftment of lockdown restrictions, and resuming research and development activities across the globe in the coming period.
The growth of the market studied can be largely attributed to the factors such as the growing burden of cancer worldwide and the increasing research and development of novel drugs and treatments. These factors are leading to increasing demand for DNA repair drugs.
The growing burden of cancer is driving the demand for DNA repair drugs. PARP inhibitors are a type of DNA repair cancer drug and are used for the treatment of various types of cancers and are also in trials as a treatment for other types of cancers. As per GLOBOCAN 2020, the estimated number of new cases in 2020 was about 19.3 million, and the number is expected to reach nearly 30.2 million by the year 2040. This is likely to provide ample opportunities for the market studied.
Additionally, the increasing research and development for novel drugs and treatments are driving market growth. For instance, in August 2021, the United Kingdom firm Artios Pharma raised a Series C round of EUR 129 million to develop cancer drugs that target the DNA repair systems of cells. Also, in April 2020, FoRx Therapeutics raised EUR 10 million in seed funding to develop a new generation of drugs that target DNA repair in cancer cells. Thus, the anticipated increase in the burden of cancer is driving the demand for DNA repair drugs.
However, the delays witnessed in product approval which can affect the revenue generation as well as lead to an increase in the cost of clinical trials, is a factor that is majorly restraining the market growth.
By drug type, olaparib is expected to hold a major share in the market. Olaparib is sold under the brand name Lynparza. It is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
The major factors bolstering the growth of the segment are the growing burden of ovarian cancer, breast cancer, pancreatic cancer, peritoneal cancer, fallopian tube cancer, and prostate cancer.
For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall, and there were more than 313,000 new cases of ovarian cancer in 2020. Additionally, according to GLOBOCAN 2020, the estimated number of new cases of breast cancer cases in 2020 was 2.26 million, and the number is estimated to reach 3.19 million by the year 2040.
Several market players are also engaged in the implementation of strategic initiatives that are contributing to the market growth. For instance, in March 2022, AstraZeneca and MSD’s Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. This factor is anticipated to boost the growth of the segment.
The factors fueling the market growth in the region are the increasing focus on research and development, the growing number of investments pertaining to DNA repair research as well as the increasing burden of cancer disorders in the country.
For instance, as per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020, and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer, with 284,200 cases. These factors are leading to an increased demand for DNA repair drugs in the region.
Additionally, according to March 2022 update by the Florida State University, a Florida State University College of Medicine researcher has made a discovery that alters the understanding of how the body’s DNA repair process works and may lead to new chemotherapy treatments for cancer and other disorders. This indicates that the increasing focus on research and development can boost the development of DNA repair drugs that can augment the market growth in the region.
Also, in October 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for niraparib offered by Janssen Pharmaceutical Companies for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer. Thus, due to the above-mentioned developments, the regional market is expected to witness significant growth over the forecast period.
The DNA repair drugs market is nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are AstraZeneca plc, Clovis Oncology, GlaxoSmithKline plc., Pfizer Inc., and Onxeo.
This product will be delivered within 2 business days.
The COVID-19 pandemic is an unprecedented health concern and has significantly impacted the DNA repair drugs market. DNA repair drugs are majorly used for cancer. Thus, the delay in cancer treatment worldwide significantly impacted the demand for these drugs after the onset of the pandemic. For instance, as per the study published in December 2021 on "Impact of the COVID-19 pandemic on the diagnosis of new cancers: A national multicentre study of the Veterans Affairs Healthcare System, from 2018 through 2020, there were 4.1 million cancer-related encounters, 3.9 million relevant procedure, and 251,647 new cancer cases diagnosed. As per the study, as compared to the annual averages in 2018 through 2019, colonoscopies in 2020 decreased by 45%, whereas prostate biopsies, chest computed tomography scans, and cystoscopies decreased by 29%, 10%, and 21%, respectively, and new cancer diagnoses decreased by 13% to 23%. Thus, as there was a delay in diagnostic procedures, the demand for oncology drugs was also negatively impacted.
Also, as per a February 2021 published article titled, "Dramatic drop in new cancer drug trials during the COVID-19 pandemic", the data revealed a 60% decrease in new clinical trials for cancer drugs and biological therapies during the pandemic, further highlighting the Impact that COVID-19 is having on oncology research. This further indicates the slow growth of the market amid the pandemic. Moreover, COVID-19 also led to supply chain disruptions of pharmaceutical and biotechnology products. However, the scope of market growth is expected to expand amid the pandemic with the introduction of vaccines, upliftment of lockdown restrictions, and resuming research and development activities across the globe in the coming period.
The growth of the market studied can be largely attributed to the factors such as the growing burden of cancer worldwide and the increasing research and development of novel drugs and treatments. These factors are leading to increasing demand for DNA repair drugs.
The growing burden of cancer is driving the demand for DNA repair drugs. PARP inhibitors are a type of DNA repair cancer drug and are used for the treatment of various types of cancers and are also in trials as a treatment for other types of cancers. As per GLOBOCAN 2020, the estimated number of new cases in 2020 was about 19.3 million, and the number is expected to reach nearly 30.2 million by the year 2040. This is likely to provide ample opportunities for the market studied.
Additionally, the increasing research and development for novel drugs and treatments are driving market growth. For instance, in August 2021, the United Kingdom firm Artios Pharma raised a Series C round of EUR 129 million to develop cancer drugs that target the DNA repair systems of cells. Also, in April 2020, FoRx Therapeutics raised EUR 10 million in seed funding to develop a new generation of drugs that target DNA repair in cancer cells. Thus, the anticipated increase in the burden of cancer is driving the demand for DNA repair drugs.
However, the delays witnessed in product approval which can affect the revenue generation as well as lead to an increase in the cost of clinical trials, is a factor that is majorly restraining the market growth.
Key Market Trends
Olaparib Segment is Expected to Hold a Major Market Share in the DNA Repair Drugs Market
By drug type, olaparib is expected to hold a major share in the market. Olaparib is sold under the brand name Lynparza. It is a medication for the maintenance treatment of BRCA-mutated advanced ovarian cancer in adults. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair.
The major factors bolstering the growth of the segment are the growing burden of ovarian cancer, breast cancer, pancreatic cancer, peritoneal cancer, fallopian tube cancer, and prostate cancer.
For instance, according to the World Cancer Research Fund International, ovarian cancer is the 8th most commonly occurring cancer in women and the 18th most common cancer overall, and there were more than 313,000 new cases of ovarian cancer in 2020. Additionally, according to GLOBOCAN 2020, the estimated number of new cases of breast cancer cases in 2020 was 2.26 million, and the number is estimated to reach 3.19 million by the year 2040.
Several market players are also engaged in the implementation of strategic initiatives that are contributing to the market growth. For instance, in March 2022, AstraZeneca and MSD’s Lynparza (olaparib) was approved in the United States for the adjuvant treatment of patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer who have already been treated with chemotherapy either before or after surgery. This factor is anticipated to boost the growth of the segment.
North America is Anticipated to Observe a Significant Growth in the DNA Repair Drugs Market
The factors fueling the market growth in the region are the increasing focus on research and development, the growing number of investments pertaining to DNA repair research as well as the increasing burden of cancer disorders in the country.
For instance, as per the 2020 Statistics by the National Cancer Institute (NCI), about 1,806,590 cases of cancer were diagnosed in the United States in 2020, and the number of cancer survivors is projected to reach 2.2 million by 2030. Moreover, as per the NCI, in 2021, the most prevalent cancer type is breast cancer, with 284,200 cases. These factors are leading to an increased demand for DNA repair drugs in the region.
Additionally, according to March 2022 update by the Florida State University, a Florida State University College of Medicine researcher has made a discovery that alters the understanding of how the body’s DNA repair process works and may lead to new chemotherapy treatments for cancer and other disorders. This indicates that the increasing focus on research and development can boost the development of DNA repair drugs that can augment the market growth in the region.
Also, in October 2019, the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for niraparib offered by Janssen Pharmaceutical Companies for the treatment of patients with BRCA1/2 gene-mutated metastatic castration-resistant prostate cancer. Thus, due to the above-mentioned developments, the regional market is expected to witness significant growth over the forecast period.
Competitive Landscape
The DNA repair drugs market is nearly consolidated with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are AstraZeneca plc, Clovis Oncology, GlaxoSmithKline plc., Pfizer Inc., and Onxeo.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Onxeo
- FoRx Therapeutics
- Artios Pharma Limited
- Merck KGaA
- Debiopharm Group
- Breakpoint Therapeutics
- Luciole Pharmaceuticals
- Repare Therapeutics
- AstraZeneca Plc
- AbbVie
- Johnson & Johnson
- Pfizer Inc.
- ClovisOncology Inc.
- GlaxoSmithKline plc.
Methodology
LOADING...
